Lixte Biotechnology

Yahoo Finance • last year

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A PASADENA, CA, Sept. 20, 2023 (GLOBE NEW... Full story

Yahoo Finance • last year

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

PASADENA, CA, June 23, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE” or the “Company”) announced today that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regain... Full story

Yahoo Finance • 2 years ago

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

First clinical trial seeking to determine if the potentiation of cytotoxic chemotherapy by LB-100 occurs in cancer patients as has been shown in multiple animal studies across a spectrum of cancers PASADENA, CA, April 24, 2023 (GLOBE NE... Full story

Yahoo Finance • 2 years ago

LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH

THE RESEARCH SHOWS THAT PP2A, THE TARGET OF LIXTE’S LEAD CLINICAL COMPOUND, LB-100, WHEN DEFICIENT, ENHANCES EFFECTS OF IMMUNE CHECKPOINT BLOCKADEOF CANCER BY A PREVIOUSLY UNAPPRECIATED MECHANISM PASADENA, CA, Feb. 14, 2023 (GLOBE NEWSW... Full story

Yahoo Finance • 2 years ago

LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

--THE STUDY ESTABLISHES A NOVEL CONCEPT OF “TUMOR SUPPRESSIVE DRUG RESISTANCE” --THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE MODULATORS WAS HIGHLY EFFECTIVE IN KILLING CANCER CELLS IN SEVERAL PRE-CLINICAL CANCER... Full story

Yahoo Finance • 2 years ago

LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP

PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc.(Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced t... Full story

Yahoo Finance • 3 years ago

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

Bernardsis internationally recognized for his contributions to the development of effective anti-cancer drugs from their earliest stages through clinical use PASADENA, CA, June 15, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings,... Full story

Yahoo Finance • 3 years ago

LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

PASADENA, CA, April 14, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it ha... Full story

Yahoo Finance • 3 years ago

Healthcare Breakthroughs: Atai, Nova Mentis, PolarityTE, and LIXTE; Biomed Leaders Report Latest Advances in Regenerative Tissue Technology, Psychedelics, and New Therapeutics for Autism, Mental Health and Cancers

NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: PolarityTE, Inc. (NASDAQ: PTE), Nova Mentis Life Sc... Full story

Yahoo Finance • 3 years ago

LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market

PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it ha... Full story

Yahoo Finance • 3 years ago

LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations

PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announces that Professor René Bernard... Full story